At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
In Brief
A Phase 2 clinical trial evaluating incobotulinumtoxin A for Androgenetic Alopecia. Active but no longer recruiting, targeting 20 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not associated with scarring or other internal disease called 'pattern hair loss'. This type of hair loss is medically called 'androgenic or androgenetic alopecia'. In men it is typically called 'male pattern baldness' whereas in women it is called 'female pattern baldness' and in both cases is hereditary meaning there will be a history of relatives that describe having the same condition.
Study Details
Timeline
Interventions
Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area